Trial Profile
A phase I study to assess the pharmacokinetics of a single dose of a slow-release solid injection of EPT1647 in healthy male volunteers
Status:
Not yet recruiting
Phase of Trial:
Phase I
Latest Information Update: 17 Jun 2016
Price :
$35
*
At a glance
- Drugs Afamelanotide (Primary)
- Indications Actinic keratosis; Erythropoietic protoporphyria; Pemphigus; Squamous cell cancer; Vitiligo
- Focus Pharmacokinetics
- Sponsors Clinuvel Pharmaceuticals
- 17 Jun 2016 New trial record